A Good Time to Get Into Biotech
Some high-quality biotech names are trading at substantial discounts, as the market reacts to near-term concerns over pricing and biosimilar competition.
Some high-quality biotech names are trading at substantial discounts, as the market reacts to near-term concerns over pricing and biosimilar competition.
Stefan Quenneville: We recently published our annual biotech moat and pipeline report, where we do a deep dive to look at the pipeline progress of our covered companies and the impact on their economic moats.
The key takeaway is that despite worries about pricing and biosimilar competition in the U.S., the overall fundamentals continue to improve in the sector given the strong pipeline productivity.
In addition, given the recent sell-off in biotechs in the last month or so, this is the first time in a number of years where the group, in aggregate, is trading at a discount to our fair value estimates. So, we think it's a good time to get into some high-quality names in the sector.
Among our wide-moat companies, Amgen (AMGN) is currently one of our best ideas. We think that the company is undervalued because the market is too focused on the near-term risks from biosimilar competition and is underappreciating the cost-cutting initiatives the company is taking and the long-term potential of its pipeline.
Among narrow-moat names, several rare-disease companies have been hit by worries about pricing because many of their drugs have price tags of more than $100,000 per year. Nevertheless, we think that the rare-disease space is one of the most attractive niches in the biotech space. As such, Biomarin (BMRN), Vertex (VRTX), and Alexion (ALXN) are currently very attractively valued.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.